Stock Traders Buy Large Volume of Biogen Put Options (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) saw unusually large options trading activity on Wednesday. Stock traders purchased 5,799 put options on the company. This represents an increase of 230% compared to the average volume of 1,759 put options.

Hedge Funds Weigh In On Biogen

Several large investors have recently added to or reduced their stakes in BIIB. Align Financial LLC lifted its holdings in Biogen by 339.3% during the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 95 shares during the last quarter. Bell Investment Advisors Inc acquired a new position in Biogen during the second quarter worth $27,000. Canton Hathaway LLC acquired a new position in shares of Biogen during the 3rd quarter worth approximately $31,000. Ashurst Perkins Coie Trust Co increased its holdings in shares of Biogen by 92.2% during the third quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 83 shares during the period. Finally, Balance Wealth Partners LLC acquired a new stake in Biogen during the third quarter worth about $39,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Price Performance

Shares of NASDAQ:BIIB opened at $249.65 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.95. Biogen has a one year low of $138.00 and a one year high of $258.78. The company has a market capitalization of $36.89 billion, a PE ratio of 106.69, a price-to-earnings-growth ratio of 2.87 and a beta of 0.09. The stock has a fifty day moving average of $226.29 and a 200-day moving average of $200.70.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The company had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.63 billion. During the same quarter in the prior year, the company earned $4.81 earnings per share. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. As a group, equities analysts anticipate that Biogen will post 12.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BIIB. Wall Street Zen downgraded shares of Biogen from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. JPMorgan Chase & Co. raised shares of Biogen from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $210.00 to $300.00 in a research report on Monday, October 12th. Royal Bank Of Canada upped their target price on Biogen from $256.00 to $272.00 and gave the stock an “outperform” rating in a research report on Thursday. Mizuho lifted their price target on shares of Biogen from $221.00 to $241.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Finally, Zacks Research raised shares of Biogen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $251.00.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q3 earnings beat expectations: Biogen reported adjusted EPS of $2.62 versus consensus of roughly $2.00 and revenue of $2.80 billion, up 10.6% year over year and ahead of estimates. Growth products, including newer rare-disease treatments and acquired assets, helped offset continued pressure on older multiple-sclerosis drugs. What Biogen Doubters Overlooked
• Positive Sentiment: Analyst sentiment improved materially: Needham and Baird raised their targets to $290, UBS increased its target to $300 while maintaining a buy rating, and RBC raised its target to $272 with an outperform rating. Argus also upgraded Biogen from hold to buy with a $280 target. Analysts Increase Their Forecasts on Biogen
• Positive Sentiment: Growth narrative is strengthening: RBC said Biogen has returned to growth, while management raised the low end of its 2026 earnings outlook. The company’s growth portfolio reportedly rose 49% and now represents 63% of core pharmaceutical sales, supporting the view that newer products can replace declining legacy revenue. Biogen Swings Back to Growth
• Positive Sentiment: Alzheimer’s pipeline remains a potential catalyst: Biogen plans to present long-term and real-world data for its Alzheimer’s portfolio at the November CTAD conference, including data on lecanemab and investigational diranersen. Biogen CTAD 2026 Data Announcement
• Neutral Sentiment: Analyst views are not unanimous: Truist and TD Cowen remain bullish, but Morgan Stanley kept an equal-weight rating with a $238 target, below the current trading level. Barclays also maintained equal weight despite lifting its target to $230. Biogen Analyst Target Updates
• Negative Sentiment: Risks remain: Biogen swung to a quarterly loss because of transaction-related charges, while higher costs led management to tighten its full-year adjusted EPS outlook. Unusually heavy put-option activity also signals that some traders remain defensive.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.